chr16-3729044-A-G

Variant summary

Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BS1BS2

The NM_004380.3(CREBBP):​c.6003T>C​(p.Asn2001Asn) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00254 in 1,587,542 control chromosomes in the GnomAD database, including 13 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).

Frequency

Genomes: 𝑓 0.0024 ( 1 hom., cov: 32)
Exomes 𝑓: 0.0026 ( 12 hom. )

Consequence

CREBBP
NM_004380.3 synonymous

Scores

2

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:7

Conservation

PhyloP100: -0.662

Publications

1 publications found
Variant links:
Genes affected
CREBBP (HGNC:2348): (CREB binding protein) This gene is ubiquitously expressed and is involved in the transcriptional coactivation of many different transcription factors. First isolated as a nuclear protein that binds to cAMP-response element binding protein (CREB), this gene is now known to play critical roles in embryonic development, growth control, and homeostasis by coupling chromatin remodeling to transcription factor recognition. The protein encoded by this gene has intrinsic histone acetyltransferase activity and also acts as a scaffold to stabilize additional protein interactions with the transcription complex. This protein acetylates both histone and non-histone proteins. This protein shares regions of very high sequence similarity with protein p300 in its bromodomain, cysteine-histidine-rich regions, and histone acetyltransferase domain. Mutations in this gene cause Rubinstein-Taybi syndrome (RTS). Chromosomal translocations involving this gene have been associated with acute myeloid leukemia. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Feb 2009]
CREBBP Gene-Disease associations (from GenCC):
  • Rubinstein-Taybi syndrome
    Inheritance: AD Classification: DEFINITIVE Submitted by: ClinGen, Illumina
  • Rubinstein-Taybi syndrome due to CREBBP mutations
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, G2P
  • Menke-Hennekam syndrome 1
    Inheritance: AD Classification: STRONG Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.79).
BP6
Variant 16-3729044-A-G is Benign according to our data. Variant chr16-3729044-A-G is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 95059.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-0.662 with no splicing effect.
BS1
Variant frequency is greater than expected in population sas. GnomAd4 allele frequency = 0.0024 (365/152192) while in subpopulation SAS AF = 0.00456 (22/4826). AF 95% confidence interval is 0.00309. There are 1 homozygotes in GnomAd4. There are 171 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check.
BS2
High AC in GnomAd4 at 365 AD gene.

Variant Effect in Transcripts

ACMG analysis was done for transcript: NM_004380.3. You can select a different transcript below to see updated ACMG assignments.

RefSeq Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
CREBBP
NM_004380.3
MANE Select
c.6003T>Cp.Asn2001Asn
synonymous
Exon 31 of 31NP_004371.2
CREBBP
NM_001079846.1
c.5889T>Cp.Asn1963Asn
synonymous
Exon 30 of 30NP_001073315.1

Ensembl Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
CREBBP
ENST00000262367.10
TSL:1 MANE Select
c.6003T>Cp.Asn2001Asn
synonymous
Exon 31 of 31ENSP00000262367.5
CREBBP
ENST00000382070.7
TSL:1
c.5889T>Cp.Asn1963Asn
synonymous
Exon 30 of 30ENSP00000371502.3

Frequencies

GnomAD3 genomes
AF:
0.00240
AC:
365
AN:
152074
Hom.:
1
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.000362
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00295
Gnomad ASJ
AF:
0.0216
Gnomad EAS
AF:
0.000193
Gnomad SAS
AF:
0.00455
Gnomad FIN
AF:
0.0000943
Gnomad MID
AF:
0.00633
Gnomad NFE
AF:
0.00285
Gnomad OTH
AF:
0.00479
GnomAD2 exomes
AF:
0.00357
AC:
735
AN:
205960
AF XY:
0.00371
show subpopulations
Gnomad AFR exome
AF:
0.000471
Gnomad AMR exome
AF:
0.00332
Gnomad ASJ exome
AF:
0.0181
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00290
Gnomad OTH exome
AF:
0.00450
GnomAD4 exome
AF:
0.00256
AC:
3674
AN:
1435350
Hom.:
12
Cov.:
33
AF XY:
0.00265
AC XY:
1889
AN XY:
713450
show subpopulations
African (AFR)
AF:
0.00115
AC:
38
AN:
33092
American (AMR)
AF:
0.00342
AC:
145
AN:
42416
Ashkenazi Jewish (ASJ)
AF:
0.0205
AC:
527
AN:
25752
East Asian (EAS)
AF:
0.00
AC:
0
AN:
38706
South Asian (SAS)
AF:
0.00513
AC:
432
AN:
84262
European-Finnish (FIN)
AF:
0.0000970
AC:
4
AN:
41248
Middle Eastern (MID)
AF:
0.00993
AC:
57
AN:
5740
European-Non Finnish (NFE)
AF:
0.00200
AC:
2213
AN:
1104528
Other (OTH)
AF:
0.00433
AC:
258
AN:
59606
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.491
Heterozygous variant carriers
0
259
518
777
1036
1295
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
90
180
270
360
450
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00240
AC:
365
AN:
152192
Hom.:
1
Cov.:
32
AF XY:
0.00230
AC XY:
171
AN XY:
74386
show subpopulations
African (AFR)
AF:
0.000361
AC:
15
AN:
41544
American (AMR)
AF:
0.00294
AC:
45
AN:
15284
Ashkenazi Jewish (ASJ)
AF:
0.0216
AC:
75
AN:
3472
East Asian (EAS)
AF:
0.000194
AC:
1
AN:
5158
South Asian (SAS)
AF:
0.00456
AC:
22
AN:
4826
European-Finnish (FIN)
AF:
0.0000943
AC:
1
AN:
10610
Middle Eastern (MID)
AF:
0.00680
AC:
2
AN:
294
European-Non Finnish (NFE)
AF:
0.00285
AC:
194
AN:
67984
Other (OTH)
AF:
0.00474
AC:
10
AN:
2108
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.500
Heterozygous variant carriers
0
22
43
65
86
108
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
10
20
30
40
50
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00298
Hom.:
0
Bravo
AF:
0.00245
Asia WGS
AF:
0.00231
AC:
9
AN:
3478

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:3
Aug 01, 2025
CeGaT Center for Human Genetics Tuebingen
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

CREBBP: BP4, BP7

Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided

Sep 21, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

not specified Benign:2
Aug 23, 2013
Eurofins Ntd Llc (ga)
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Feb 08, 2013
Genetic Services Laboratory, University of Chicago
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Rubinstein-Taybi syndrome Benign:1
Jan 20, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Inborn genetic diseases Benign:1
Jul 22, 2016
Ambry Genetics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.79
CADD
Benign
0.14
DANN
Benign
0.29
PhyloP100
-0.66
Mutation Taster
=100/0
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.010
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs200998860; hg19: chr16-3779045; COSMIC: COSV106054290; API